Astragalus mongholicus and Angelica sinensis compound alleviates nephrotic hyperlipidemia in rats

Chinese Medical Journal

Volumn 113, Issue 4, 2000, Pages 310-314

  Li, Jingzi ^a   Yu, Lei ^a   Li, Ningjun ^a   Wang, Haiyan ^a  

^a PEKING UNIVERSITY HEALTH SCIENCE CENTER   (China)

Author keywords

Angelica sinensis; Astragalus mongholicus; Hyperlipidemia; Nephrotic syndrome

Indexed keywords

ANTILIPEMIC AGENT; ASTRAGALUS MONGHOLICUS; LIPOPROTEIN LIPASE; PHOSPHATIDYLCHOLINE STEROL ACYLTRANSFERASE; UNCLASSIFIED DRUG;

ANGELICA SINENSIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DRUG EFFECT; ENZYME ACTIVITY; GENE OVEREXPRESSION; HYPERLIPIDEMIA; LIPID BLOOD LEVEL; LIPID METABOLISM; MALE; NEPHROTIC SYNDROME; NONHUMAN; RAT;

ANGELICA SINENSIS; ANIMALS; ASTRAGALUS PLANT; BLOOD PROTEINS; DRUGS, CHINESE HERBAL; HYDROXYMETHYLGLUTARYL COA REDUCTASES; HYPERLIPIDEMIAS; LIPIDS; LIPOPROTEIN LIPASE; LIVER; MALE; NEPHROTIC SYNDROME; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, LDL; RNA, MESSENGER;

EID: 0034015532     PISSN: 03666999     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (24)

1. Oda H, Keane WF. Lipids in progression of renal disease. Kidney Int Suppl 1997;62:S36-S38.
2. Wanner C, Greiber S, Kramer-Guth A, et al. Lipids and progression of renal disease: role of modified low density lipoprotein and lipoprotein(a). Kidney Int Suppl 1997;52:S102-S106.
3. Ruan XZ, Varghese Z, Fernando R, et al. Cytokine regulation of low-density lipoprotein receptor gene transcription in human mesangial cells. Nephrol Dial Transplant 1998;13:1391-1397.
4. Quaschning T, Kōniger M, Krämer Guth A, et al. Receptor-mediated lipoprotein uptake by human glomerular cells: comparison with skin fibroblasts and HepG2 cells. Nephrol Dial Transplant 1997; 12:2528-2536.
5. Li LY, Yu H, Pan JS, et al. A study on protein metabolism in nephrotic patients treated with Chinese herbs. Chin J Intern Med 1995;34:670-672.
6. Gu J, Pan JS, Cao H, et al. Chinese herbs and protein intake on protein turnover in nephrotic rats. Chin J Nephrol 1992;8:226-227.
7. Lu Y, Li JZ, Zheng X, et al. Lipid-lowering effect of Pravastatin on glomerulo- scleroses protection and treatment. Chin J Intern Med 1997;36:242-245.
8. Li LY, Wang HY, Zhu SL, et al. Hepatic albumin's mRNA in nephrotic syndrome rats treated with Chinese herbs. Natl Med J China 1995;75:276-279.
9. Chomczynski P, Sacchi N. Single-step method of RNA isolation by acid-guanidium-thiocyanate-phenol-chloroform extraction. Anal Biochem 1987;162:156-159.
10. Krans RM, Levy RI, Fredrickson DS, et al. Selective measurement of two different triglyceride lipase activities in rat post-heparin plasma. J Lipid Res 1973;14:286-295.
11. Zhang XY, Cui RL, Li L, et al. A modified method for measuring lecithin-cholesterol acyltransferase (LCAT) and its significance in kidney disease. Chin J Nephrol Dial Transplant 1995;4: 318-319.
12. Warwick GL, Packard CJ, Demant T, et al. Metabolism of apolipoprotein B-containing lipoproteins in subjects with nephrotic-rang proteinuria. Kidney Int 1991;40:129-138.
13. Warwick GL, Caslake MJ. Low-density lipoprotein metabolism in the nephrotic syndrome. Metabolism 1990;39:187-192.
14. Rudling M. Hepatic mKNA levels for the LDL receptor and HMG-CoA reductase show coordinate regulation in vivo. J Lipid Res 1992;33:493-501.
15. de Sain-van der Velden MG, Kaysen GA, Barrett HA, et al. Increased VLDL in nephrotic patients results form a decreased catabolism while increased LDL results from increased synthesis. Kidney Int 1998;53:994-1001.
16. Vaziri ND, Liang KH. Hepatic HMG-CoA reductase gene expression during the course of puromycin-induced nephrosis. Kidney Int 1995;48:1979-1985.
17. Mohamed AEHT, Anna C, James CMC, et al. Studies of alteration of hepatic cholesterol metabolism in puromycin-induced nephrotic syndrome in rats. Kidney Int 1993;44:789-794.
18. Vaziri ND, Uang KH. Down-regulation of hepatic LDL receptor expression in experimental nephrosis. Kidney Int 1996;50: 887-893.
19. Wheeler DV, Bemard DB. Lipid abnormalities in the nephrotic syndrome: causes, consequences, and treatment. Am J Kidney Dis 1994;23:331-346.
20. Hireano T, Ebara T, Furekawa S, et al. Mechanism of hypertriglyceridemia in Dahl salt-sensitive rats, an animal model of spontaneous nephrotic syndrome. Metablism 1994;43:248-256.
21. Wheeler DC. Abnormalities of lipoprotein metabolism in CAPD patients. Kidney Int Suppl 1996;50:S41-S46.
22. Subbaiah PV, Rodby RA. Abnormal acyltransferase activities and accelerated cholesterylester transfer in patients with nephrotic syndrome. Metabolism 1994;43:1126-1133.
23. Li LY, Chen MH, Tong TJ, et al. The molecular basis of Chinese herbs (Astragali and Angelicae) on increasing serum albumin synthesis in nephrotic rats. Nephrology 1998;4:1-6.
24. Gröne HJ, Hohbach J, Gröne EF, et al. Modulation of glomerular sclerosis and interstitial fibrosis by native and modified lipoproteins. Kidney Int Suppl 1996;49:S18-S22.